|
Active substance |
encorafenib |
|
Holder |
Pierre Fabre Santé Benelux N.V. |
|
Status |
Closed |
|
Indication |
in combination with cetuximab, for the treatment of adult patients with metastatic colorectal carcinoma with a BRAFV600E mutation, who have received prior systemic therapy |
|
Public documents |
|
|
Last update |
11/08/2022 |
Braftovi®
Last updated on 10/09/2024